A large-scale study of bone marrow involvement in patients with Hodgkin's lymphoma.

This study was designed to identify variables that can predict bone marrow involvement (BMI) in Hodgkin's lymphoma (HL), and to analyze the benefit of bilateral over unilateral bone marrow trephine biopsy (BMB). From 1982 to 2000, BMB had been performed at diagnosis in 1161 patients with HL who had been followed from the institutions participating in the Piemonte Hodgkin's Disease Registry. Six hundred and sixteen patients (53%) had received bilateral BMB, and the remaining 545 patients (47%) received unilateral BMB. The relationships between BMB results and other clinical features were retrospectively studied with both univariate and multivariate analyses. Ninety-two patients (8%) showed BMI: 51 of them were staged with bilateral and 41 with unilateral BMB. Among the 92 patients with BMI, a second extranodal involvement was present in only 25 patients (27%). In multivariate analysis, the 5 independent factors that predicted for BMI were B symptoms, infradiaphragmatic involvement, mixed cellularity (MC) and lymphocyte depleted (LD) histology, involvement of > or = 4 lymphatic areas, and liver involvement. The probability of BMI according to the presence of these variables was distributed as follows: 0.3%, 2.5%, 7.6%, and 27% in patients positive for 0, 1, 2, and > or = 3 factors, respectively. Among 51 patients staged with bilateral BMB, BMI was shown in both specimens in 33 cases (65%), whereas the positivity was limited to only 1 of the 2 specimens in the remaining 18 cases (35%). A score based on 5 variables can predict the probability of BMI, and BMB could be avoided in patients with a score of 0 and a probability of BMI of < 0.5%. When BMB is needed, the superiority of bilateral over unilateral biopsy is suggested.

[1]  A. Alavi,et al.  Utility of FDG-PET scanning in lymphoma by WHO classification. , 2003, Blood.

[2]  J. Matthews,et al.  Optimum trephine length in the assessment of bone marrow involvement in patients with diffuse large cell lymphoma. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  J. Radford,et al.  The value of bone marrow examination in the staging of Hodgkin's lymphoma: a review of 955 cases seen in a regional cancer centre , 2002, British journal of haematology.

[4]  M. Slovak,et al.  Diagnostic utility of bilateral bone marrow examination , 2002, Cancer.

[5]  B. Bain Bone marrow trephine biopsy. , 2001, Journal of clinical pathology.

[6]  J Kotzerke,et al.  2‐(fluorine‐18)fluoro‐2‐deoxy‐D‐glucose positron emission tomography in the detection and staging of malignant lymphoma , 2001, Cancer.

[7]  G. Jerusalem,et al.  Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. , 2001, Haematologica.

[8]  S. Hain,et al.  2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  L. Avioli,et al.  Hodgkin's disease , 1969, Bone Marrow Transplantation.

[10]  G. Demir,et al.  Magnetic resonance imaging of bone marrow versus bone marrow biopsy in malignant lymphoma , 1999, Pathology & Oncology Research.

[11]  J. Armitage,et al.  A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. , 1998, The New England journal of medicine.

[12]  J Kotzerke,et al.  Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Â. Maiolino,et al.  Clinical factors predictive of bone marrow involvement in Hodgkin's disease. , 1997, Leukemia & lymphoma.

[14]  S. Fava,et al.  Bone marrow biopsy for staging Hodgkin's lymphoma: the value of bilateral or unilateral trephine biopsy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  S. Hancock,et al.  Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  V. Diehl,et al.  Bone marrow involvement in Hodgkin's disease: an analysis of 135 consecutive cases. German Hodgkin's Lymphoma Study Group. , 1995, Journal of Clinical Oncology.

[17]  P. Gobbi,et al.  Estimate of expected survival at diagnosis in Hodgkin's disease: a means of weighting prognostic factors and a tool for treatment choice and clinical research. A report from the International Database on Hodgkin's Disease (IDHD). , 1994, Haematologica.

[18]  P. Gobbi,et al.  MOPP/EBV/CAD hybrid chemotherapy with or without limited radiotherapy in advanced or unfavorably presenting Hodgkin's disease: a report from the Italian Lymphoma Study Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  K. McNally,et al.  Audit of bone marrow trephines. , 1992, Journal of clinical pathology.

[20]  P. Donnan,et al.  A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. The Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party. , 1992, Leukemia & lymphoma.

[21]  A. Shields,et al.  Detection of lymphomatous bone marrow involvement with magnetic resonance imaging. , 1991, Blood.

[22]  A. Santoro,et al.  Alternating versus hybrid MOPP-ABVD in Hodgkin's disease: the Milan experience. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  M Tubiana,et al.  Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  N. Nissen,et al.  Prognostic factors in Hodgkin's disease stage IV , 1988, European journal of haematology.

[25]  E. Macintyre,et al.  The value of staging bone marrow trephine biopsy in Hodgkin's Disease , 1987, European journal of haematology.

[26]  A. Shields,et al.  The detection of bone marrow involvement by lymphoma using magnetic resonance imaging. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  A. Santoro,et al.  Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. , 1986, Annals of internal medicine.

[28]  G. Papa,et al.  Bone Marrow Involvement at Onset of Hodgkin's Disease , 1983, Tumori.

[29]  D. Huhn,et al.  Assessment of bone marrow histology in Hodgkin's disease: correlation with clinical factors , 1982, British journal of haematology.

[30]  D. O'Carroll,et al.  Bone marrow manifestations of Hodgkin's disease , 1976, Cancer.

[31]  G. Bonadonna,et al.  Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP , 1975, Cancer.

[32]  C. Bloomfield,et al.  Bilateral trephine bone marrow biopsies in lymphoma and other neoplastic diseases. , 1975, Annals of internal medicine.

[33]  S. Rosenberg Hodgkin's disease of the bone marrow. , 1971, Cancer research.

[34]  M Tubiana,et al.  Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.

[35]  R. Silver,et al.  Importance of bone marrow biopsy in the clinical staging of hodgkin's disease , 1970, Cancer.

[36]  Treatment of Hodgkin's disease. , 1967, The Medical annals of the District of Columbia.